{"a":[{"_":"FDA clears Lantheus’ Alzheimer’s PET imaging agent Tauklarify","$":{"href":"/medtech/fda-clears-lantheus-alzheimers-pet-imaging-agent-tauklarify","hreflang":"en"}}]}
RegulatoryapprovedTauklarifyPositive
AI Analysis
Summary
Lantheus received FDA clearance for Tauklarify, a PET imaging agent for Alzheimer's disease, ahead of its $8 billion acquisition by Curium.
Outcome Details
FDA clearance for Tauklarify, a PET imaging agent for Alzheimer's
Importance:8/10
Sentiment:
0.80
FDA approvalAlzheimer'sPET imagingMedical deviceAcquisition
Related Companies
Read the original article
Published by FierceBiotech on August 17, 2026 7:53 AM